Skip to main content

Sundhedsøkonomisk evaluering

I DaCHE har vi stor erfaring med sundhedsøkonomisk evaluering. Vi udarbejder CUA/CEA og omkostningsanalyser, yder sparring omkring sundhedsøkonomiske evalueringer (herunder studiedesign, indsamling af data og valg af outcomemål), vejleder ph.d.-studerende og underviser i økonomisk evaluering. Hvis du vil vide mere er du velkommen til at kontakte projektleder Line Planck Kongstad

Eksempler på igangværende/fremtidige projekter:

CEA/CUA

  • IMPROVE-IT2 – CUA af brugen af ctDNA til at øge andelen, der overlever tilbagefald af tarmkræft
  • Økonomisk evaluering af en langsigtet patient-centreret intervention til at forbedre medicinsk adherence hos psoriasispatienter lokalbehandlet med kortikosteroidholdige præparater
  • Økonomiske evalueringer relateret til RCT studier tilknyttet DCCC ctDNA
  • Omkostninger ved screening for tyk- og endetarmskræft i Danmark
  • Økonomisk evaluering af PET/CT for overlevelse af lungekræft
  • Økonomisk evaluering af et AI-baseret system til at overvåge patienter for adverse events på hospitaler (WARD-projektet)
  • Cost-effectiveness of insulin pump use among diabetes 1 patients: a matched controlled study Economic consequences of a new course of rehabilitation and care for older adults after hip fracture

Omkostningsanalyser

  • Halling, C et al. Resource consequences of gastrointestinal bleedings in critically ill patients: Evidence from the SUP-ICU trail. Healthcare utilization the last year of life in Danish patients with uncurable cancer. A national register-based study.

Metodemæssige bidrag til CEA/CUA

  • A longitudinal study of quality of life in incurable cancer patients using both the EQ-5D-5L and the EORTC QLQ-C30D.

Eksempler på afsluttede projekter: CEA/CUA

  • Hellström L, Kruse M, Christensen TN, Wolf RT & Eplov LF (2021): Cost-effectiveness analysis of a supported employment intervention for people with mood and anxiety disorders in Denmark – the IPS-MA intervention, Nordic Journal of Psychiatry
  • Pedersen, S.S., Andersen, C.M., Ahm, R. et al. Efficacy and cost-effectiveness of a therapist-assisted web-based intervention for depression and anxiety in patients with ischemic heart disease attending cardiac rehabilitation [eMindYourHeart trial]: a randomised controlled trial protocol. BMC Cardiovasc Disord 21, 20 (2021). https://doi.org/10.1186/s12872-020-01801-w
  • Skovsgaard CV, Kruse M, Hjollund NHI, Maribo T, Thurah A. Cost-effectiveness of telehealth-based outpatient follow-up for tight control of disease activity in rheumatoid arthritis: Economic evaluation of the TeRA randomised controlled trial. Submitted to Arthritis Care & Research, 2021.
  • Morso L, Olsen KR., Schiøttz-Christensen B, Søndergaard J, Swoden, G., Christiansen DH. Effectiveness of stratified care for back pain in Danish primary care: A randomised controlled trial. (under review)
  • Wolf RT et al "Cost-effectiveness of a transdiagnostic psychotherapy program for youth with common mental health problems"
  • Christensen TN, Kruse M, Hellström L, Eplov LF. Cost-utility and cost-effectiveness of individual placement support and cognitive remediation in people with severe mental illness: Results from a randomized clinical trial. Eur Psychiatry. 2020 Dec 21;64(1):e3.
  • Bring C, Kruse M, Ankarfeldt MZ, Brünés N, Pedersen M, Petersen J, Andersen O. Post-hospital medical respite care for homeless people in Denmark: a randomized controlled trial and cost-utility analysis. BMC Health Serv Res. 2020 Jun 5;20(1):508
  • Hyldig, N, Joergensen, JS, Wu, C, Bille, C, Vinter, CA, Sorensen, JA, Mogensen, O, Lamont, RF, Möller, S, Kruse, M. Cost‐effectiveness of incisional negative pressure wound therapy compared with standard care after caesarean section in obese women: a trial‐based economic evaluation. BJOG 2019; 126: 619– 627.
  • Morso L, Schiottz-Christensen B, Sondergaard J, Andersen NV, Pedersen F, Olsen KR, et al. The effectiveness of a stratified care model for non-specific low back pain in Danish primary care compared to current practice: study protocol of a randomised controlled trial. Trials. 2018;19(1):315.
  • Sopina E, Sørensen J, Beyer N, Hasselbalch SG, Waldemar G. Cost-effectiveness of a randomised trial of physical activity in Alzheimer’s disease: a secondary analysis exploring patient and proxy-reported health-related quality of life measures in Denmark. BMJ Open. 2017;7(6).
  • Petersen LB, Olsen KR, Matzen LH, Vaeth M, Wenzel A. Economic and health implications of routine CBCT examination before surgical removal of the mandibular third molar in the Danish population. Dentomaxillofac Radiol. 2015;44(6):20140406.
  • Gyrd-Hansen D, Olsen KR, Bollweg K, Kronborg C, Ebinger M, Audebert HJ, 2015. Cost-effectiveness estimate of prehospital thrombolysis. Results of the PHANTOM-S Study. Neurology, 84(11): 1090-1097
  • Olsen KR, Hansen C, Abrahamsen B. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases. Osteoporos Int. 2013;24(10):2639-47.
  • Gyrd-Hansen D, Olsen KR, 2012. Vaccinepris og sygefravær afgørende for omkostningseffektivitet af rotavirus vaccination. Ugeskrift for Læger. (the Danish Medical Journal); 174(8): 480-483
  • Sopina E, Ashton T. Cost-effectiveness of a cervical screening program with human papillomavirus vaccine. International Journal of Technology Assessment in Health Care. 2011;27(4):290-7.
  • Højgaard B, Olsen KR, Pisinger C, Tønnesen H, Gyrd-Hansen D, 2011. The potential of smoking cessation programmes and a smoking ban in public places: comparing gain in life expectancy and cost effectiveness. Scandinavian Journal of Public Health. 39(8): 785-796 Doi: 10.1177/14034948.11421416
  • Hojgaard B, Olsen KR, Sogaard J, Gyrd-Hansen D, Sorensen TI. [Obesity related health care costs assessed from BMI or waist circumference--secondary publication]. Ugeskr Laeger. 2009;171(43):3068-71.
  • Olsen KR, Bojesen SE, Gerdes AM, Lindorff-Larsen K, Bernstein IT. Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer. Int J Technol Assess Health Care. 2007;23(1):89-95.
  • Olsen KR, Bilde L, Juhl HH, Kjaer NT, Mosbech H, Evald T, et al. Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish Smoking Cessation Database. Eur J Health Econ. 2006;7(4):255-64.
  • Petersen KD, Gyrd-Hansen D, Dahl R, 2005. Health-Economic Analyses of subcutaneous Specific Immunotherapy for grass pollen and mite allergy: Allergol et Immunopathol, 33(6):296-302
  • Christensen PM, Brixen K, Gyrd-Hansen D, Kristiansen IS, 2005. Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol, 96(5):387-96
  • Nielsen R and Gyrd-Hansen D, 2002. Prenatal screening for cystic fibrosis. An economic analysis. Health Economics, 11: 285-299
  • Gyrd-Hansen D. 2000. Cost benefit analysis of mammography screening in Denmark based on discrete ranking data. International Journal of Health Technology Assessment in Health Care, 16(3): 811-821
  • Gyrd-Hansen D, 1999. The relative economics of screening for colorectal cancer, breast cancer and cervical cancer. Critical Reviews in Oncology/Hematology, 32(2): 133-144
  • Gyrd-Hansen D., Søgaard J., Kronborg O. 1998, Colorectal cancer screening: efficiency and cost effectiveness. Health Economics, 7: 9-20
  • Gyrd-Hansen D., 1997. Is it cost effective to introduce screening programmes for colorectal cancer? Health Policy, 41 189-199
  • Gyrd-Hansen D, 1997.The relative economics of screening for cervical cancer, mammae cancer and colorectal cancer.The European Journal of Cancer, 33 (9): 25-s26
  • Gyrd-Hansen D, Hølund B, Andersen P, 1996. Omkostningseffektivitetsanalyse af alternative screeningsprogrammer mod livmoderhalskræft [Cost effectiveness analyses of a range of screening programmes for cervical cancer] Ugeskrift for Læger, 158/35: 4912-4915
  • Gyrd-Hansen D, Hølund B, Andersen P, 1995. A cost-effectiveness analysis of cervical cancer screening: health policy implications. Health Policy, 34: 35-51

Omkostningsanalyser

  • Korsholm M, Gyrd-Hansen D; Mogensen O, Möller S, Sopina L, Jørgensen SL, Jensen PT, 2019. Long term resource consequences of a nationwide introduction of robotic surgery for women with early stage endometrial cancer. Gynecologic Oncology, 154(2):411-419. doi: 10.1016/j.ygyno.2019.05.027
  • Herbild L, Bech M, Gyrd-Hansen D, Christensen M, Werge T, Nilsen KA, 2011. Assessing the effects of local clinic guidelines of pharmacogenetic testing on treatment costs among psychiatric patients. An application of multilevel modelling in the analysis of observational data from Danish hospitals. Scandinavian Journal of Public Health; 39: 147–155
  • Kruse M, Sørensen J, Davidsen M, Gyrd-Hansen D, 2009. Short and long term labour market consequences of coronary heart disease. A register based follow-up study. European Journal of Cardiovascular Prevention and Rehabilitation, 16(3): 387-391
  • Højgaard, B, Olsen KR, Søgaard, J, Gyrd-Hansen, D, Sørensn, TIA, 2009. Fedme-relatererede sundhedsomkostninger bestemt med BMI eller taljeomkreds – sekundærpublikation. Ugeskrift for Læger, 171(43): 3063-3068
  • Højgaard B, Sørensen T, Olsen KR, Søgaard J, Gyrd-Hansen D, 2008. Economic Costs of Abdominal Obesity. Obesity Facts. The European Journal of Obesity vol 1(3); 146-154
  • Højgaard B, Gyrd-Hansen D, Olsen KR, Søgaard J. Sørensen T, 2008. Waist Circumference and Body Mass Index as Predictors of Health Care Costs. PlosOne, 3(7); e2619
  • Kruse M, Davidsen M, Madsen M, Gyrd-Hansen D, Sørensen J, 2008.  Cost of Heart Disease and Risk Behaviour. Scandinavian Journal of Public Health, 36(8): 850-856.
  • Bech M and Gyrd-Hansen D, 2000. Cost implications of routine screening of women 50-69 years in the County of Funen, Health Policy, 54: 125-141

Metodemæssige bidrag til CEA/CUA

  • Meacock, R., Kristensen, S. R., and Sutton, M. (2014). The Cost-Effectiveness Of Using Financial Incentives To Improve Provider Quality: A Framework And Application. Health economics, 23(1):1–13 
  • Kruse M, Sørensen J, Gyrd-Hansen D, 2012.  Future costs in cost-effectiveness analysis: An empirical assessment. European Journal of Health Economics, 13(1): 63-70
  • Bech, M, Christiansen, T & Gyrd-Hansen, D, 2006.  Handling VAT in economic evaluations: should prices include VAT? Applied Health Economics and Health Policy, 5(4): 209-213 
  • Kristiansen IS and Gyrd-Hansen D, 2004. Cost effectiveness analysis based on the number-needed-to-treat: common sense or non-sense? Health Economics, 13(1): 9-19

Sidst opdateret: 09.05.2024